Shopping Cart
Remove All
Your shopping cart is currently empty
Pyr3 is a selective transient receptor potential canonical channel 3 inhibitor. Pyr3 inhibits TRPC3-mediated Ca2+ influx in a dose-dependent manner(IC50 = 700 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | In Stock | In Stock | |
| 2 mg | $44 | In Stock | In Stock | |
| 5 mg | $70 | In Stock | In Stock | |
| 10 mg | $98 | In Stock | In Stock | |
| 25 mg | $226 | In Stock | In Stock | |
| 50 mg | $382 | In Stock | In Stock | |
| 100 mg | $538 | In Stock | In Stock | |
| 200 mg | $777 | - | In Stock | |
| 500 mg | $1,180 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $78 | In Stock | In Stock |
| Description | Pyr3 is a selective transient receptor potential canonical channel 3 inhibitor. Pyr3 inhibits TRPC3-mediated Ca2+ influx in a dose-dependent manner(IC50 = 700 nM). |
| Targets&IC50 | TRPC3:700 nM |
| In vitro | Pyr3 becomes apparent at 0.3 μM and is almost complete at 3 μM. Ca2+ influx is inhibited by Pyr3 in cells co-expressing TRPC3 plus TRPC6 but not in cells co-expressing TRPC1 plus TRPC5. The Ang II-induced NFAT translocation is suppressed by Pyr3 (IC50 = 0.05 μM), but weakly by Pyr2 (IC50 = 2 μM) in a concentration-dependent manner[1]. |
| Molecular Weight | 456.63 |
| Formula | C16H11Cl3F3N3O3 |
| Cas No. | 1160514-60-2 |
| Smiles | CCOC(=O)c1cnn(c1C(F)(F)F)-c1ccc(NC(=O)C(Cl)=C(Cl)Cl)cc1 |
| Relative Density. | 1.54 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (219 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.76 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.